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Antidepressant use and risk of suicide and attempted suicide or 
self harm in people aged 20 to 64: cohort study using a primary 
care database
Carol Coupland,1 Trevor Hill,1 Richard Morriss,2 Antony Arthur,3 Michael Moore,4 
Julia Hippisley-Cox1
AbstrAct
ObjeCtive
To assess the associations between different 
antidepressant treatments and the rates of suicide 
and attempted suicide or self harm in people with 
depression.
Design
Cohort study.
setting
Patients registered with UK general practices 
contributing data to the QResearch database.
PartiCiPants
238 963 patients aged 20 to 64 years with a first 
diagnosis of depression between 1 January 2000 
and 31 July 2011, followed up until 1 August 2012.
exPOsures
Antidepressant class (tricyclic and related 
antidepressants, selective serotonin reuptake 
inhibitors, other antidepressants), dose, and duration 
of use, and commonly prescribed individual 
antidepressant drugs. Cox proportional hazards 
models were used to calculate hazard ratios adjusting 
for potential confounding variables.
Main OutCOMe Measures
Suicide and attempted suicide or self harm during 
follow-up.
results
During follow-up, 87.7% (n=209 476) of the cohort 
received one or more prescriptions for 
antidepressants. The median duration of treatment 
was 221 days (interquartile range 79–590 days). During 
the first five years of follow-up 198 cases of suicide and 
5243 cases of attempted suicide or self harm occurred. 
The difference in suicide rates during periods of 
treatment with tricyclic and related antidepressants 
compared with selective serotonin reuptake inhibitors 
was not significant (adjusted hazard ratio 0.84, 95% 
confidence interval 0.47 to 1.50), but the suicide rate 
was significantly increased during periods of treatment 
with other antidepressants (2.64, 1.74 to 3.99). The 
hazard ratio for suicide was significantly increased for 
mirtazapine compared with citalopram (3.70, 2.00 to 
6.84). Absolute risks of suicide over one year ranged 
from 0.02% for amitriptyline to 0.19% for mirtazapine. 
There was no significant difference in the rate of 
attempted suicide or self harm with tricyclic 
antidepressants (0.96, 0.87 to 1.08) compared with 
selective serotonin reuptake inhibitors, but the rate of 
attempted suicide or self harm was significantly higher 
for other antidepressants (1.80, 1.61 to 2.00). The 
adjusted hazard ratios for attempted suicide or self 
harm were significantly increased for three of the most 
commonly prescribed drugs compared with 
citalopram: venlafaxine (1.85, 1.61 to 2.13), trazodone 
(1.73, 1.26 to 2.37), and mirtazapine (1.70, 1.44 to 
2.02), and significantly reduced for amitriptyline 
(0.71, 0.59 to 0.85). The absolute risks of attempted 
suicide or self harm over one year ranged from 1.02% 
for amitriptyline to 2.96% for venlafaxine. Rates were 
highest in the first 28 days after starting treatment and 
remained increased in the first 28 days after stopping 
treatment.
COnClusiOn
Rates of suicide and attempted suicide or self harm 
were similar during periods of treatment with 
selective serotonin reuptake inhibitors and tricyclic 
and related antidepressants. Mirtazapine, 
venlafaxine, and trazodone were associated with the 
highest rates of suicide and attempted suicide or self 
harm, but the number of suicide events was small 
leading to imprecise estimates. As this is an 
observational study the findings may reflect 
indication biases and residual confounding from 
severity of depression and differing characteristics of 
patients prescribed these drugs. The increased rates 
in the first 28 days of starting and stopping 
antidepressants emphasise the need for careful 
monitoring of patients during these periods.
Introduction
Rates of suicide and self harm are greatly increased in 
people with depression1 2 and reduction of these risks is 
a major consideration when treating such patients. Par-
adoxically, although antidepressants have been shown 
WhAt Is AlreAdy knoWn on thIs topIc
Depression is a common condition, and antidepressants are used extensively in its 
treatment
Rates of suicide and attempted suicide are higher in people with depression
It is unclear to what extent suicide and attempted suicide rates vary when people 
with depression are treated with different antidepressants
WhAt thIs study Adds
Rates of suicide and attempted suicide or self harm were similar during periods of 
treatment with selective serotonin reuptake inhibitors and tricyclic and related 
antidepressants overall, but were higher during periods of treatment with other 
antidepressants, although this may reflect indication biases and residual 
confounding
Suicide and self harm rates tend to be higher when antidepressants are started or 
stopped so the same care over risk assessment should be carried out when 
treatment is stopped as when it is started
 open access
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to be effective in reducing the symptoms of depres-
sion3 4 there is concern that rates of suicide and self 
harm may actually be increased by treatment, particu-
larly in younger people.5 6 A meta-analysis of 372 ran-
domised placebo controlled trials of antidepressants 
found that among adults aged less than 25 the risk of 
suicidal behaviour was increased during treatment 
with antidepressants, whereas no association was 
found in adults aged 25 to 64, and in those aged 65 or 
more the risk was reduced.7 These findings were sup-
ported by a meta-analysis of eight observational studies 
involving more than 200 000 patients,8 which found an 
increased risk of suicide among adolescents treated 
with selective serotonin reuptake inhibitors compared 
with no antidepressant treatment, but a reduced risk 
among adults.
The meta-analysis by Stone7 indicated possible differ-
ences in risk of suicidal behaviour between different 
antidepressants, but these findings were based on a 
small number of events. In a cohort study, venlafaxine 
was associated with an increased risk of suicide and 
attempted suicide compared with three other antide-
pressants,9 although the authors concluded that this 
may have been due to residual confounding. In another 
cohort study the reported rates of suicide and attempted 
suicide were similar for different antidepressants, 
except for a higher rate of suicidal acts in users of ven-
lafaxine compared with selective serotonin reuptake 
inhibitors, but this association was reduced in second-
ary analyses.10 In a cohort study of adults aged 65 or 
more with depression the highest rates of attempted 
suicide or self harm were in those treated with venlafax-
ine, mirtazapine, or trazodone.11
Uncertainty remains about the risks of suicide and 
self harm for different antidepressants and whether 
these risks vary by dose and duration of use. This is par-
ticularly important to determine, now that suicide rates 
in the United Kingdom and many other countries have 
started to increase after a period when they were 
decreasing.12–14 We carried out a cohort study in people 
aged 20 to 64 to investigate the associations between 
different antidepressants and the risk of suicide and 
attempted suicide or self harm.
Methods
This cohort study was designed to assess the associa-
tions of antidepressant treatment and several different 
adverse outcomes, including suicide and attempted sui-
cide or self harm. Full details of the study design and 
methods are in the study protocol.15 
study cohort
The study cohort was selected from a large primary care 
database (QResearch, version 34). QResearch is derived 
from the anonymised health records of over 12 million 
patients from more than 600 general practices across 
the United Kingdom. The practices record data using 
the Egton Medical Information Systems medical records 
system. Recorded information includes data on 
patients’ diagnoses, symptoms, consultations, refer-
rals, test results, and prescriptions. The database is 
linked at patient level to Office for National Statistics 
mortality data.
The study sample comprised an open cohort of 
patients with a first recorded diagnosis of depression 
between 1 January 2000 and 31 July 2011, at age 20 to 64. 
We used diagnostic Read codes to identify patients with 
a diagnosis of depression, using case definitions that 
have been used in previous studies.11 16 17 Patients were 
eligible for inclusion only if their diagnosis occurred at 
least 12 months after registration with a study practice 
and the date of the installation of the practice computer 
system. Patients were eligible for inclusion regardless 
of whether they received prescriptions for antidepres-
sants. To reduce the risk of indication bias, we consid-
ered patients who received prescriptions for 
antidepressants but did not have a recorded diagnosis 
of depression to be ineligible, as the prescriptions may 
have been for conditions other than depression.
We excluded patients from the cohort if they had a 
previous recorded diagnosis of depression; were tempo-
rary residents; had a diagnosis of schizophrenia, bipo-
lar disorder, or other type of psychosis; or had been 
prescribed lithium or antimanic drugs at the study entry 
date. Patients were also excluded if they had received 
prescriptions for an antidepressant either before the 
study start date (1 January 2000), before their date of 
registration with the practice (if later), before the age of 
20, or more than 36 months before their first recorded 
diagnosis of depression.
We defined the date of entry into the study (index 
date) as the date of the first recorded diagnosis of 
depression, or the date of the first prescription for an 
antidepressant if earlier. Participants were followed up 
until the earliest of date of death, date of leaving the 
practice, or the end of follow-up (1 August 2012). Most 
analyses were restricted to the first five years of fol-
low-up.
Outcomes
We identified suicides during follow-up as patients 
with either a code for suicide or an open verdict on 
their linked death certificate (using international clas-
sification of diseases codes, ninth and 10th revisions) 
or patients with a Read code in their medical record for 
attempted suicide or self harm who died within 30 
days. We identified cases of attempted suicide or self 
harm from the patients’ medical records, based on 
Read codes used in other studies.9 16 18 We only consid-
ered the first attempted suicide or self harm event in 
the analysis of this outcome, and excluded patients 
with a previous attempted suicide or self harm event 
recorded at baseline.
exposure data
We extracted details of all individual prescriptions for 
antidepressants during follow-up, including the issue 
date, the type and dose of antidepressant, dosage 
instructions, and quantity of tablets prescribed. To 
determine the duration of each prescription in days we 
divided the number of tablets prescribed by the dosing 
instructions (for example, number of tablets to be taken 
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each day). Where the number of tablets prescribed was 
recorded but dosing instructions were missing or not 
sufficiently detailed (<5% of prescriptions) we used an 
assumed duration, taking account of the number of tab-
lets prescribed as in our previous study.19 We calculated 
the daily dose of each prescription by multiplying the 
specified dose of each tablet by the number of tablets to 
be taken each day. Prescriptions for the same drug 
issued on the same day were counted as a single pre-
scription and the doses combined.
For the main analyses we grouped antidepressants 
according to the major classes as given in the British 
National Formulary—namely, tricyclic and related anti-
depressants (section 4.3.1), selective serotonin reuptake 
inhibitors (section 4.3.3), monoamine oxidase inhibi-
tors (section 4.3.2), and other antidepressants (section 
4.3.4). Where patients received prescriptions for differ-
ent drugs within a class or for drugs from different 
classes on the same date we classified these as com-
bined prescriptions.
To enable a comparison of dose between the antide-
pressant classes, for each prescription we converted the 
prescribed daily dose to a number of defined daily 
doses, using the values assigned by the World Health 
Organization’s Collaborating Centre for Drug Statistics 
Methodology (www.whocc.no/atc_ddd_index). WHO’s 
definition of a defined daily dose is the assumed aver-
age maintenance dose each day for a drug used for its 
main indication in adults (for example, the defined 
daily dose for citalopram is 20 mg, for fluoxetine is 
20 mg, and for amitriptyline is 75 mg), although this 
may not necessarily reflect the recommended dose, and 
individual patients may be prescribed higher or lower 
doses.
Where numbers were sufficient, we also assessed 
individual antidepressants. As in our previous study, 
we examined the 11 most commonly prescribed individ-
ual antidepressants separately.11
Confounding variables
We considered as confounding variables those likely to 
be associated with the risk of suicide or attempted sui-
cide or self harm, or with the likelihood of receiving 
treatment for different antidepressants, based on vari-
ables included in our previous study of antidepressants 
in people aged 65 or more.11
Confounders were age at study entry date, sex, year 
of diagnosis of depression, severity of index diagnosis 
of depression (categorised as mild, moderate, or severe 
based on the Read code for the index diagnosis, using 
codes published by Martinez and colleagues16 and some 
additional classification by a member of the study 
team), deprivation (Townsend deprivation score corre-
sponding to the patient’s postcode, in fifths), smoking 
status (non-smoker, former smoker, light smoker 
(1–9 cigarettes/day), moderate smoker (10–19 ciga-
rettes/day), heavy smoker (≥20 cigarettes/day), not 
recorded), alcohol intake (none, trivial (<1 UK unit/day), 
light (1–2 units/day), medium (3–6 units/day,) heavy 
(7–9 units/day,) very heavy (>9 units/day), not 
recorded), ethnic group (categorised as white/not 
recorded or non-white (Indian, Pakistani, Bangladeshi, 
other Asian, black African, black Caribbean, Chinese, 
other including mixed)), comorbidities at baseline (cor-
onary heart disease, diabetes, hypertension, cancer, 
epilepsy or seizures, hypothyroidism, osteoarthritis, 
asthma or chronic obstructive airways disease), and use 
of other drugs at baseline (statins, non-steroidal anti-in-
flammatory drugs, aspirin, antihypertensive drugs, 
anticonvulsants, hypnotics or anxiolytics, oral contra-
ceptives, hormone replacement therapy). In addition, 
the analysis of suicide as an outcome included 
attempted suicide or self harm at baseline as a con-
founding variable. In the analysis of attempted suicide 
or self harm we also adjusted for stroke or transient 
ischaemic attack, rheumatoid arthritis, osteoporosis, 
liver disease, renal disease, obsessive-compulsive dis-
order, antipsychotics, bisphosphonates, and anticoag-
ulants. These were not included in the analysis of 
suicide because of the smaller number of events, and 
the prevalence of these confounders was less than 1% 
in the study cohort.
statistical analysis
We used Cox’s proportional hazards models to assess 
the associations between exposure to antidepressant 
drugs and the two outcomes (suicide and attempted sui-
cide or self harm). To account for patients starting and 
stopping treatment during follow-up and also changing 
between treatments, we treated antidepressant expo-
sure as a time varying exposure. We considered patients 
to have been exposed to a drug if there were no gaps of 
more than 90 days between the end of one prescription 
and the start of the next. In the analysis of attempted 
suicide or self harm we excluded patients who already 
had the outcome recorded at baseline. The main analy-
ses were based on the first five years of follow-up after 
the study entry date, by censoring any follow-up after 
this date. We used robust standard errors to account for 
clustering of patients within practices.20
In the analysis we calculated unadjusted and 
adjusted analysis hazard ratios for antidepressant 
class, by comparing current treatment using tricyclic 
and related antidepressants, other antidepressants, 
and combined antidepressants with treatment using 
selective serotonin reuptake inhibitors. We included a 
category of “no current treatment” for periods of time 
where patients were not treated with antidepressants, 
which also included follow-up time for patients who 
were not prescribed any antidepressants during fol-
low-up. The number of patients prescribed monoamine 
oxidase inhibitors was too small for this group to be 
analysed, so we excluded from the analyses those 
patients prescribed monoamine oxidase inhibitors at 
any time.
Analyses were also carried out for dose categories 
within each antidepressant class (≤0.5, >0.5 and ≤1.0, 
and >1.0 defined daily doses) using the middle dose cat-
egory for selective serotonin reuptake inhibitors as the 
reference group, and we carried out tests for trend using 
the doses within each class as continuous variables. We 
analysed duration of antidepressant use and time since 
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stopping within each antidepressant class as a time 
varying exposure (categorised as no use (reference 
group), 1–28 days, 29–84 days, and ≥85 days after start-
ing treatment, and 1–28 days, 29–84 days, and 85–182 
days after stopping treatment). We only allocated fol-
low-up time to the time since stopping treatment cate-
gories if patients did not switch directly to another 
antidepressant, otherwise we allocated their follow-up 
time to time since starting categories for the new drug. 
Analyses were carried out for the 11 most commonly 
prescribed antidepressants, with the most commonly 
prescribed antidepressant (citalopram) as the reference 
category.
To determine whether significant differences existed 
between the antidepressant classes and between the 
individual drugs, we carried out Wald’s tests. We tested 
for interactions between drug class and age (continu-
ous) and carried out subgroup analyses split by age 
band (20–29, 30–39, 40–49, and 50–64 years). We 
assessed the proportional hazards assumption using 
log minus log plots.
As a sensitivity analysis we repeated the analyses 
restricted to patients who received at least one prescrip-
tion for an antidepressant during follow-up, excluding 
untreated patients. We carried out this analysis because 
patients who were untreated during follow-up might dif-
fer from treated patients in ways that would be difficult to 
account for in the analysis (such as having a dislike of 
tablets, a preference for non-drug treatments, or less 
severe depression), so we carried out this sensitivity 
analysis to test whether our results were robust to exclu-
sion of these patients. We also carried out an analysis 
restricted to the first year of follow-up and a further anal-
ysis including all outcome events that occurred within 
the entire follow-up period. These analyses were done to 
assess whether any associations between antidepressant 
drugs and the risks of suicide and attempted suicide or 
self harm for five yearsʼ follow-up were also present in 
analyses over one year and over the entire follow-up 
period. In particular the baseline characteristics are less 
likely to change during one year, and fewer switches 
occur between different antidepressant drugs, so the 
results from the one year analysis are less likely to be 
influenced by residual confounding. We performed anal-
yses for the entire follow-up since these have increased 
power and include long durations of use. In an addi-
tional analysis we used a minimum gap of 30 days 
between the end of one prescription and the start of the 
next rather than 90 days to classify periods of non-use. 
We carried out a further analysis of the suicide outcome 
restricted to deaths specifically coded as suicide on the 
linked death certificate and not including open verdicts 
or suicides only identified from the medical records.
We calculated absolute risks of both outcomes over 
one year, accounting for the confounding variables 
using adjusted hazard ratios from the analysis for one 
year of follow-up based on the method described by 
 Altman et al.21
To maximise power we included all eligible patients 
from the database in the analyses. We used a P value of 
less than 0.01 (two tailed) to determine statistical signif-
icance. Analyses were carried out using Stata (v12.1).
results
From 1 January 2000 to 31 July 2011, 327 235 patients had 
a first diagnosis of depression between the ages of 20 
and 64. A total of 88 272 (27.0%) patients were excluded 
from the study cohort because they had schizophrenia, 
bipolar disorder, or other psychoses or had been pre-
scribed lithium or antimanic drugs (7152 patients, 2.2%) 
and/or had been prescribed an antidepressant before 
the study entry date aged less than 20, or more than 36 
months before the recorded date of depression (83 824 
patients, 25.6%); 2704 patients met both exclusion cri-
teria. This left 238 963 patients from 687 practices in the 
study cohort (fig 1).
Table 1 shows the baseline characteristics of the 
study cohort. The mean age was 39.5 (SD 11.1) years, and 
there were 92 935 men (38.9%) and 146 028 (61.1%) 
women. The total number of person years of follow-up 
was 1 307 326, with a median of 5.2 (interquartile range 
2.5–8.2) years.
antidepressant treatment during follow-up
During follow-up, 87.7% of patients (n=209 476) received 
one or more prescriptions for an antidepressant, with 
3 337 336 prescriptions for antidepressants received in 
total; 29 708 patients (14.2%) only received a single pre-
scription during follow-up. The median duration of 
treatment with antidepressants during follow-up was 
221 (interquartile range 79–590) days, with 36.6% of 
treated patients having one or more years of treatment 
and 5.5% having five or more years.
Selective serotonin reuptake inhibitors were the most 
commonly prescribed drug class, comprising 71.3% 
(2 379 668) of prescriptions for antidepressants; there 
were 533 798 prescriptions (16.0%) for tricyclic and 
related antidepressants and 422 079 (12.7%) for the 
Patients with rst diagnosis of depression aged 20-64 years; between 1 Jan 2010 and 31 Aug 2011
(excluding temporary residents and patients with previous recorded diagnosis of depression) (n=327 235)
Included in nal study cohort (n=238 963; 73.0%)
Excluded (n=88 272; 27.0%):
  Patients with schizophrenia, bipolar disorder or other psychoses or had been
    prescribed lithium or antimanic drugs (n=7152; 2.2%)
  Patients prescribed an antidepressant before study entry date, before age 20
    or >36 months before recorded diagnosis of depression (n=83 824; 25.6%)
Fig 1 | Flow chart showing selection of patients included in study cohort. 2704 patients met both exclusion criteria
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group of other antidepressants. Monoamine oxidase 
inhibitors were the least commonly prescribed class, 
comprising only 1791 prescriptions (0.05%) in 156 
patients. There were 83 784 combined prescriptions 
where two or more different antidepressant drugs were 
prescribed on the same day.
Figure 2 shows the number of prescriptions during 
follow-up for the 11 most commonly prescribed antide-
pressants, which comprised 97.7% of all prescriptions 
for antidepressants. Citalopram was the most com-
monly prescribed antidepressant (1 023 255 prescrip-
tions, 31.5% of total). Citalopram and fluoxetine 
accounted for 77.6% of prescriptions for selective sero-
tonin reuptake inhibitors, amitriptyline and dosulepin 
for 77.3% of prescriptions for tricyclic and related anti-
depressants, and venlafaxine and mirtazapine for 
90.7% of prescriptions for other antidepressants. Sup-
plementary tables 1s to 3s show the distributions of 
baseline characteristics according to the first antide-
pressant prescribed for these 11 drugs.
associations with suicide
After omitting the patients with prescriptions for mono-
amine oxidase inhibitors, there were 238 807 patients in 
the study cohort. During the first five years of follow-up 
198 cases of suicide occurred in this study cohort, giving 
table 1 | Characteristics of study cohort at baseline. values 
are numbers (percentages) unless stated otherwise
Characteristics
study cohort 
(n=238 963)
Men 92 935 (38.9)
Women 146 028 (61.1)
Age (years):
 20–29 51 212 (21.4)
 30–39 77 141 (32.3)
 40–49 59 260 (24.8)
 50–59 39 573 (16.6)
 60–64 11 777 (4.9)
Mean (SD) age (years) 39.5 (11.1)
Ethnic group:
 White/not recorded 227 451 (95.2)
 Indian 1922 (0.8)
 Pakistani 1714 (0.7)
 Bangladeshi 1000 (0.4)
 Other Asian 991 (0.4)
 Caribbean 1520 (0.6)
 Black African 1386 (0.6)
 Chinese 307 (0.1)
 Other 2672 (1.1)
Depression severity (index diagnosis):
 Mild 171 208 (71.7)
 Moderate 59 140 (24.8)
 Severe 8615 (3.6)
Smoking status:*
 Recorded 233 290 (97.6)
 Non-smoker 110 849 (47.5)
 Former smoker 35 132 (15.1)
 Light smoker (1–9 cigarettes/day) 24 104 (10.3)
 Moderate smoker (10–19 cigarettes/day) 40 546 (17.4)
 Heavy smoker (≥20 cigarettes/day) 22 659 (9.7)
Alcohol consumption:*
 Recorded 203 189 (85.0)
 Non-drinker 55 253 (27.2)
 Trivial (<1 UK unit/day) 77 579 (38.2)
 Light (1–2 units/day) 51 310 (25.3)
 Moderate (3–6 units/day) 14 482 (7.1)
 Heavy (7–9 units/day) 2174 (1.1)
 Very heavy (>9 units/day) 2391 (1.2)
Townsend deprivation fifth:*
 Recorded 230 762 (96.6)
 1 (least deprived) 45 021 (19.5)
 2 46 207 (20.0)
 3 48 293 (20.9)
 4 47 063 (20.4)
 5 (most deprived) 44 178 (19.1)
Comorbidities:
 Coronary heart disease 4109 (1.7)
 Diabetes 7371 (3.1)
 Hypertension 17 217 (7.2)
 Stroke or transient ischaemic attack 1741 (0.7)
 Asthma or chronic obstructive airways disease 31 816(13.3)
 Cancer 3810 (1.6)
 Epilepsy or seizures 3325 (1.4)
 Hypothyroidism 5267 (2.2)
 Obsessive-compulsive disorder 494 (0.2)
 Rheumatoid arthritis 1301 (0.5)
 Osteoarthritis 7228 (3.0)
 Osteoporosis 867 (0.4)
 Liver disease 698 (0.3)
 Renal disease 549 (0.2)
Continued
table 1 (continued) | Characteristics of study cohort at 
baseline. values are numbers (percentages) unless  
stated otherwise
 Previous attempted suicide/self harm 10 174 (4.3)
Drugs at baseline:
 Anticonvulsants 2672 (1.1)
 Antihypertensives 25 344 (10.6)
 Antipsychotics 836 (0.4)
 Anticoagulants 1073 (0.5)
 Aspirin 7159 (3.0)
 Bisphosphonates 854 (0.4)
 Hypnotics or anxiolytics 11 354 (4.8)
 Non-steroidal anti-inflammatory drugs 12 725 (5.3)
 Statins 10 823 (4.5)
 Oral contraceptives† 27 396 (18.8)
 Hormone replacement therapy† 7207 (4.9)
*Percentages out of total of recorded values.
†Women only.
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Fig 2 | total number of prescriptions issued during 
follow-up for most commonly prescribed antidepressants
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an incidence rate of 22 per 100 000 person years (43 per 
100 000 in men and 9 per 100 000 in women). Of these 
suicide cases, 156 were only identified from the linked 
death records, 18 only from primary care records, and 24 
from both sources. Among the 180 cases identified from 
linked death records, 48 were coded as open verdicts.
Suicide rates did not differ significantly when compar-
ing periods of tricyclic antidepressant treatment with 
selective serotonin reuptake inhibitor treatment 
(adjusted hazard ratio 0.84, 95% confidence interval 0.47 
to 1.50), but rates increased significantly during periods 
of treatment with the other antidepressants compared 
with selective serotonin reuptake inhibitors (2.64, 1.74 to 
3.99, table 2). Adjusted hazard ratios tended to increase 
with dose for selective serotonin reuptake inhibitors 
(P=0.02), but not for tricyclic antidepressants (P=0.6) or 
other antidepressants (P=0.9) (table 2).
In the analysis of the 11 most commonly prescribed 
drugs, the adjusted hazard ratio was significantly 
increased (at P<0.01) for mirtazapine compared with 
citalopram (3.70, 2.00 to 6.84). There was also some 
indication of an increased risk for venlafaxine com-
pared with citalopram (2.23, 1.14 to 4.39, P=0.02).
Hazard ratios were highest in the first 28 days 
after starting treatment for tricyclic antidepressants, 
 selective serotonin reuptake inhibitors, and, particu-
larly, for other antidepressants, and also in the first 28 
days after stopping treatment (fig 3).
table 2 | unadjusted and adjusted hazard ratios for suicide by antidepressant class, dose, and individual drug, over a five year follow-up period
variables
unadjusted analysis
P value
adjusted analysis*
no of events† Person years† Hazard ratio (95% Ci) Hazard ratio (95% Ci) P value
antidepressant class
SSRIs 79 228 233 1.00 1.00
TCAs 13 41 807 0.90 (0.51 to 1.62) 0.7 0.84 (0.47 to 1.50) 0.6
Other antidepressants 31 28 487 3.62 (2.41 to 5.44) <0.001 2.64 (1.74 to 3.99) <0.001
Combined antidepressants 2 4299 1.62 (0.39 to 6.70) 0.5 1.36 (0.32 to 5.68) 0.7
No current use 69 575 623 0.45 (0.32 to 0.62) <0.001 0.39 (0.28 to 0.55) <0.001
antidepressant class and dose categories (defined daily doses)‡
SSRIs:
 ≤ 0.5 1 16 289 0.20 (0.03 to 1.41) 0.1 0.22 (0.03 to 1.60) 0.1
 > 0.5/≤ 1.0 55 159 847 1.00 1.00
 > 1.0 21 43 226 1.74 (1.07 to 2.81) 0.02 1.55 (0.95 to 2.53) 0.08
Test for trend§ 0.002 0.02
TCAs:
 ≤ 0.5 6 23 895 0.76 (0.33 to 1.75) 0.5 0.74 (0.32 to 1.72) 0.5
 > 0.5/≤1.0 3 8502 1.14 (0.36 to 3.64) 0.8 0.95 (0.30 to 3.01) 0.9
 > 1.0 3 5363 1.78 (0.56 to 5.69) 0.3 1.46 (0.46 to 4.66) 0.5
Test for trend§ 0.3 0.6
Others:
 ≤ 0.5 5 4100 4.09 (1.65 to 10.13) 0.002 3.44 (1.38 to 8.61) 0.008
 > 0.5/ ≤ 1.0 18 13 404 4.73 (2.81 to 7.97) <0.001 3.36 (1.98 to 5.70) <0.001
 > 1.0 7 8529 3.19 (1.44 to 7.06) 0.004 2.15 (0.96 to 4.83) 0.06
Test for trend§ 0.9 0.9
antidepressant drugs
SSRIs:
 Citalopram 30 95 640 1.00 1.00
 Escitalopram 4 13 539 0.93 (0.32 to 2.64) 0.9 0.89 (0.31 to 2.55) 0.8
 Fluoxetine 27 82 935 0.96 (0.56 to 1.65) 0.9 1.03 (0.60 to 1.79) 0.9
 Paroxetine 11 16 705 1.95 (0.96 to 3.95) 0.06 1.59 (0.77 to 3.28) 0.2
 Sertraline 7 19 139 1.15 (0.51 to 2.59) 0.7 1.15 (0.51 to 2.63) 0.7
TCAs:
 Amitriptyline 4 19 845 0.64 (0.22 to 1.82) 0.4 0.68 (0.24 to 1.96) 0.5
 Dosulepin 5 12 292 1.22 (0.47 to 3.17) 0.7 1.04 (0.40 to 2.74) 0.9
 Lofepramine 2 4863 1.20 (0.29 to 5.03) 0.8 1.06 (0.25 to 4.60) 0.9
 Trazodone 2 2390 2.69 (0.64 to 11.28) 0.2 2.00 (0.47 to 8.57) 0.3
Others:
 Mirtazapine 16 10 343 5.18 (2.84 to 9.43) <0.001 3.70 (2.00 to 6.84) <0.001
 Venlafaxine 13 15 835 3.09 (1.62 to 5.91) 0.001 2.23 (1.14 to 4.39) 0.02
All other antidepressants 2 5001 1.31 (0.32 to 5.32) 0.7 1.15 (0.28 to 4.76) 0.8
Combined antidepressants 2 4299 1.72 (0.40 to 7.44) 0.5 1.45 (0.33 to 6.43) 0.6
SSRIs=selective serotonin reuptake inhibitors; TCAs=tricyclic and related antidepressants.
*Adjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group, attempted suicide or self harm at baseline, coronary 
heart disease, diabetes, hypertension, cancer, epilepsy or seizures, hypothyroidism, osteoarthritis, asthma or chronic obstructive airways disease, statins, non-steroidal anti-inflammatory 
drugs, aspirin, antihypertensives, anticonvulsants, hypnotics or anxiolytics, oral contraceptives, and hormone replacement therapy.
†Based on numbers in adjusted analysis.
‡Total numbers of events in analysis of dose are reduced owing to missing data on dose.
§Test for trend uses continuous values of dose.
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Hazard ratios changed little when patients who had 
not received any antidepressant prescriptions during 
follow-up were removed from the analysis. Hazard 
ratios were also generally similar when either just the 
first year of follow-up (see supplementary table 4s) or 
the entire follow-up period was used in the analysis, or 
when a 30 day gap was used to define unexposed peri-
ods (see supplementary table 6s). Hazard ratios tended 
to be higher, although confidence intervals were wider, 
when the analysis was restricted to the 132 cases with 
specific codes for suicide on the linked death certificate 
(see supplementary table 7s).
associations with attempted suicide or self harm
At baseline 10 174 patients (4.3%) had a record of 
attempted suicide or self harm. We omitted these 
patients from the analyses of attempted suicide or 
self harm, and also those with prescriptions for 
monoamine oxidase inhibitors, leaving 228 643 in the 
study cohort. During the first five years of follow-up 
there were 5243 cases of attempted suicide or self 
harm, giving an incidence rate of 613 per 100 000 per-
son years (737 per 100 000 in men and 517 per 100 000 
in women).
The rates of attempted suicide or self harm did not 
differ significantly for tricyclic antidepressants com-
pared with selective serotonin reuptake inhibitors (0.96, 
0.87 to 1.08) but hazard ratios were significantly 
increased during periods of treatment with other anti-
depressants (1.80, 1.61 to 2.00) or with combined pre-
scriptions (2.00, 1.54 to 2.59, table 3). In analyses of 
dose, adjusted hazard ratios increased significantly 
with dose for selective serotonin reuptake inhibitors 
and other antidepressants (both P<0.001) and also 
tended to increase with dose for tricyclic antidepres-
sants (P=0.013) (table 3).
Hazard ratios were significantly increased for three 
of the most commonly prescribed drugs compared 
with citalopram (table 3); venlafaxine (adjusted haz-
ard ratio 1.85, 95% confidence interval 1.61 to 2.13), 
trazodone (1.73, 1.26 to 2.37), and mirtazapine (1.70, 
1.44 to 2.02). The hazard ratio for amitriptyline com-
pared with citalopram was significantly reduced (0.71, 
0.59 to 0.85).
Rates of attempted suicide or self harm were highest 
in the first 28 days after starting treatment, particularly 
for other antidepressants (fig 4).
Hazard ratios were slightly reduced when patients 
who had not received any prescriptions for antidepres-
sants during follow-up were removed from the analysis. 
Results were generally similar when either just the first 
year of follow-up (see supplementary table 5s) or the 
entire follow-up period was used in the analysis, and 
also were similar when a 30 day gap was used to define 
unexposed periods (see supplementary table 7s).
interactions with age
Overall there was no significant interaction between 
drug class and age at baseline for suicide (P=0.09), 
although numbers were small. In a subgroup analysis 
split by age band the rates of suicide were lower for tri-
cyclic antidepressants and other antidepressants com-
pared with selective serotonin reuptake inhibitors in 
patients aged 20 to 29 (table 4), but these were not sta-
tistically significant. In patients aged 40 to 49 and 50 to 
64, the adjusted hazard ratios were significantly 
increased for other antidepressants compared with 
selective serotonin reuptake inhibitors.
There was some indication of an interaction between 
drug class and age for attempted suicide or self harm 
(P=0.02). Adjusted hazard ratios were similar for tricy-
clic antidepressants compared with selective serotonin 
reuptake inhibitors in all age bands, but increased 
slightly with age for other antidepressants compared 
with selective serotonin reuptake inhibitors, from 1.62 
(1.33 to 1.97) in patients aged 20–29 to 2.29 (1.75 to 3.00) 
in patients aged 50–64.
absolute risks of suicide and attempted suicide 
or self harm
Table 5 shows the absolute risks of suicide and 
attempted suicide or self harm over one year. For  suicide 
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Fig 3 | adjusted hazards and 95% confidence intervals for suicide according to time since starting and stopping different 
classes of antidepressant compared with untreated periods. numbers of events are included
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the absolute risks over one year ranged from 0.02% for 
amitriptyline to 0.19% for mirtazapine. For attempted 
suicide or self harm the absolute risks ranged from 
1.02% for amitriptyline to 2.96% for venlafaxine.
discussion
In this large cohort study of patients aged 20 to 64 with 
a diagnosis of depression, we found significant associ-
ations between different classes and types of antide-
pressants and rates of suicide and attempted suicide or 
self harm. The group of antidepressants classified as 
“other antidepressants” (mainly  comprising venlafax-
ine and mirtazapine) was associated with the highest 
rates of both of these outcomes, whereas among indi-
vidual drugs mirtazapine, venlafaxine, and trazodone 
were associated with increased risks of attempted sui-
cide or self harm compared with the most commonly 
prescribed antidepressant, citalopram.
Rates of suicide and attempted suicide or self harm 
were lowest during periods when patients were not tak-
ing antidepressants, but this is likely to reflect the 
absence of current depression or less severe depression 
table 3 | unadjusted and adjusted hazard ratios for attempted suicide or self harm by antidepressant class, dose, and individual drug over five year 
follow-up period
variables
unadjusted analysis
P value
adjusted analysis*
no of events† Person years†
Hazard ratio 
(95% Ci)
Hazard ratio (95% 
Ci) P value
antidepressant class
SSRIs 2357 215 665 1.00 1.00
TCAs 400 39 444 0.94 (0.84 to 1.04) 0.2 0.96 (0.87 to 1.08) 0.5
Other antidepressants 483 25 646 2.01 (1.81 to 2.23) <0.001 1.80 (1.61 to 2.00) <0.001
Combined antidepressants 68 3803 2.14 (1.67 to 2.74) <0.001 2.00 (1.54 to 2.59) <0.001
No current use 1741 545 180 0.40 (0.37 to 0.43) <0.001 0.36 (0.34 to 0.39) <0.001
antidepressant class and dose categories (defined daily doses)‡
SSRIs:
 ≤ 0.5 100 15 713 0.70 (0.57 to 0.85) 0.001 0.79 (0.64 to 0.97) 0.03
 > 0.5/≤1.0 1550 151 769 1.00 1.00
 > 1.0 617 39 742 2.07 (1.88 to 2.29) <0.001 1.91 (1.73 to 2.11) <0.001
Test for trend§ <0.001 <0.001
TCAs:
 ≤ 0.5 211 22 712 0.96 (0.83 to 1.11) 0.6 1.03 (0.89 to 1.20) 0.6
 > 0.5/≤ 1.0 94 7977 1.33 (1.06 to 1.66) 0.01 1.27 (1.01 to 1.60) 0.04
 > 1.0 60 4935 1.35 (1.04 to 1.75) 0.02 1.21 (0.93 to 1.58) 0.1
Test for trend§ <0.001 0.01
Others:
 ≤ 0.5 52 3793 1.65 (1.27 to 2.14) <0.001 1.63 (1.24 to 2.13) <0.001
 > 0.5/≤ 1.0 213 12 144 2.11 (1.82 to 2.45) <0.001 1.88 (1.61 to 2.19) <0.001
 > 1.0 189 7440 3.68 (3.18 to 4.26) <0.001 3.09 (2.65 to 3.60) <0.001
Test for trend§ <0.001 <0.001
antidepressant drugs
SSRIs:
 Citalopram 975 90 494 1.00 1.00
 Escitalopram 144 12 716 1.06 (0.89 to 1.27) 0.5 1.05 (0.87 to 1.26) 0.6
 Fluoxetine 834 78 458 0.95 (0.86 to 1.04) 0.3 0.92 (0.84 to 1.02) 0.1
 Paroxetine 190 15 851 1.07 (0.93 to 1.24) 0.3 0.91 (0.78 to 1.06) 0.2
 Sertraline 213 17 884 1.15 (1.00 to 1.32) 0.05 1.07 (0.92 to 1.23) 0.4
TCAs:
 Amitriptyline 133 18 818 0.68 (0.57 to 0.81) <0.001 0.71 (0.59 to 0.85) <0.001
 Dosulepin 138 11 690 1.03 (0.85 to 1.24) 0.8 1.04 (0.86 to 1.26) 0.7
 Lofepramine 62 4500 1.18 (0.93 to 1.50) 0.2 1.08 (0.84 to 1.38) 0.6
 Trazodone 45 2136 2.03 (1.48 to 2.78) <0.001 1.73 (1.26 to 2.37) 0.001
Others:
 Mirtazapine 178 9120 2.02 (1.72 to 2.38) <0.001 1.70 (1.44 to 2.02) <0.001
 Venlafaxine 276 14 440 2.09 (1.82 to 2.40) <0.001 1.85 (1.61 to 2.13) <0.001
All other antidepressants 52 4648 1.17 (0.90 to 1.52) 0.3 1.05 (0.80 to 1.39) 0.7
Combined antidepressants 68 3803 2.14 (1.67 to 2.74) <0.001 1.94 (1.50 to 2.52) <0.001
SSRIs=selective serotonin reuptake inhibitors; TCAs=tricyclic and related antidepressants.
*Adjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group, coronary heart disease, diabetes, hypertension, 
cancer, epilepsy or seizures, hypothyroidism, osteoarthritis, asthma or chronic obstructive airways disease, stroke or transient ischaemic attack, rheumatoid arthritis, osteoporosis, liver 
disease, renal disease, obsessive-compulsive disorder, statins, non-steroidal anti-inflammatory drugs, aspirin, antihypertensives, anticonvulsants, hypnotics or anxiolytics, antipsychotics, 
bisphosphonates, anticoagulants, oral contraceptives, and hormone replacement therapy.
†Based on numbers in adjusted analysis.
‡Total numbers of events in analysis of dose are reduced owing to missing data on dose.
§Test for trend uses continuous values of dose.
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during those periods rather than an indication that 
antidepressant treatment in itself increases the risks of 
suicide and attempted suicide or self harm.
The higher hazard ratios for death from suicide in 
association with venlafaxine and mirtazapine com-
pared with those for attempted suicide or self harm 
could be due to the higher lethality of these drugs in 
overdose than selective serotonin reuptake inhibitor 
antidepressants,22 but this would not explain their 
higher hazard ratios compared with tricyclic antide-
pressants, which have much higher toxicity. Also num-
bers of suicide events were small, so these results 
should be interpreted with caution.
strengths and limitations of this study
This study was large and population based with broad 
inclusion criteria. We included all eligible patients in 
the study, so the findings are generalisable to people 
aged 20 to 64 years with a diagnosis of depression in 
primary care. Recall bias is not an issue as we used data 
on prescriptions for antidepressants and potential con-
founding variables, which were prospectively recorded 
before the occurrence of the outcomes. We had detailed 
information on prescriptions for antidepressants issued 
in primary care throughout the follow-up period, so we 
were able to investigate associations with individual 
drugs, dose, and duration of treatment.
table 4 | adjusted hazard ratios for suicide and attempted suicide or self harm by antidepressant class: subgroup analyses by age group at baseline for 
five year follow-up period
antidepressant class 
and age groups
suicide attempted suicide or self harm
no of events* Hazard ratio† (95% Ci) P value no of events* Hazard ratio‡ (95% Ci) P value
SSRIs:
 20–29 11 1.00 — 743 1.00 —
 30–39 23 1.00 — 792 1.00 —
 40–49 27 1.00 — 567 1.00 —
 50–64 18 1.00 — 255 1.00 —
TCAs:
 20–29 1 0.55 (0.08 to 3.59) 0.5 111 1.00 (0.80 to 1.24) 1.0
 30–39 1 0.21 (0.03 to 1.55) 0.1 124 0.93 (0.77 to 1.12) 0.4
 40–49 5 1.11 (0.43 to 2.90) 0.8 95 0.87 (0.70 to 1.07) 0.2
 50–64 6 1.40 (0.54 to 3.59) 0.5 70 1.18 (0.89 to 1.55) 0.2
Others:
 20–29 1 0.50 (0.07 to 3.77) 0.5 124 1.62 (1.33 to 1.97) <0.001
 30–39 5 1.27 (0.46 to 3.51) 0.6 160 1.74 (1.45 to 2.10) <0.001
 40–49 10 2.79 (1.37 to 5.64) 0.004 124 1.82 (1.50 to 2.21) <0.001
 50–64 15 5.55 (2.73 to 11.29) <0.001 75 2.29 (1.75 to 3.00) <0.001
No current use:
 20–29 17 0.32 (0.13 to 0.77) 0.01 670 0.36 (0.32 to 0.42) <0.001
 30–39 20 0.30 (0.15 to 0.59) 0.001 592 0.35 (0.31 to 0.40) <0.001
 40–49 13 0.27 (0.13 to 0.56) <0.001 331 0.34 (0.29 to 0.40) <0.001
 50–64 19 0.64 (0.32 to 1.28) 0.2 148 0.41 (0.33 to 0.52) <0.001
SSRIs=selective serotonin reuptake inhibitors; TCAs=tricyclic and related antidepressants.
Results not shown for combined antidepressant treatment.
*Based on numbers in adjusted analysis.
†Adjusted for confounders listed in table 2.
‡Adjusted for confounders listed in table 3.
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Fig 4 | adjusted hazards and 95% confidence intervals for attempted suicide or self harm according to time since starting 
and stopping different classes of antidepressant compared with untreated periods. numbers of events are included
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Although all the participants had a diagnosis of 
depression, no specific studies have been carried out 
into the validity and reliability of diagnosis data for 
depression recorded by doctors in primary care contrib-
uting to the QResearch database. However, there is evi-
dence from the United Kingdom and the Netherlands 
that the diagnosis of depression by general practi-
tioners is valid and reliable.23 24
Drug safety can be assessed through meta-analyses 
of trials reporting adverse outcomes,7 but in the case of 
antidepressants and suicide or attempted suicide these 
trials tend to be short term and generally exclude 
patients with any major suicide risk or with physical or 
psychiatric comorbidity. Indication bias is the main 
concern with observational studies assessing drug 
safety, which occurs when patients are prescribed drugs 
for a condition that is itself associated with the risk of 
the adverse outcome. To reduce this bias we only 
included patients with a recorded diagnosis of depres-
sion, so that patients had the same indication for treat-
ment. This is important, as depression is associated 
with a substantially increased risk of suicide and self 
harm.1 2
Direct comparisons between groups receiving differ-
ent treatments for the same condition are still subject to 
channelling bias, where the selection of a particular 
antidepressant depends on the characteristics of the 
patient. This could have occurred in this study if drugs 
such as mirtazapine, venflaxine, and trazodone were 
more likely to be prescribed to patients at increased risk 
of suicide or attempted suicide. This may apply to venla-
faxine, particularly since guidelines from the National 
Institute for Health and Care Excellence suggest switch-
ing people with depression that does not respond well to 
initial treatment firstly to a different selective serotonin 
reuptake inhibitor or a better tolerated newer generation 
antidepressant and subsequently to an antidepressant 
of a different drug class—for example, venlafaxine, a tri-
cyclic antidepressant, or a monoamine oxidase inhibi-
tor.25 To reduce the effect of channelling bias we adjusted 
for a range of potential confounding factors that could 
influence the choice of antidepressant; for example, in 
the analysis of suicide we adjusted for attempted suicide 
at baseline as well as for many other confounders, 
including severity of depression. However, we could 
only use a basic measure of the severity of the initial 
diagnosis of depression based on Read codes, as depres-
sion severity scores are not routinely recorded in general 
practice. The Read codes used to record depression were 
generally not specific in terms of severity. Also we were 
not able to account for changes in severity of depression 
during follow-up since the severity is not recorded con-
sistently over time, so we could only include it in the 
analysis as a single baseline variable rather than a time 
varying variable; this means that the severity of depres-
sion is likely to still have a confounding influence on our 
results. In addition there may be other potential con-
founding variables, such as drug misuse or family his-
tory of psychiatric disorder,26 which were either not 
recorded on the database or not recorded in sufficient 
detail for their confounding effect to be completely 
removed by analysis. Differences in characteristics 
between patients prescribed different antidepressants 
could therefore account for some of the associations we 
found between the drugs and suicide and self harm, and 
we cannot therefore exclude the possibility of residual 
confounding.
Misclassification of drug use may have occurred, as 
patients might not have taken their prescribed antide-
pressant. This may particularly be the case for the 14% 
of patients who only received a single prescription. We 
cannot be certain of the exact dates when patients 
started and stopped taking their prescribed drug. Since 
we did not have a precise stopping date we assumed 
patients to be exposed to an antidepressant where there 
were no gaps of more than 90 days between the end of 
one prescription and the start of the next, to allow for 
any antidepressant use if patients had accumulated 
extra tablets over time and also so that outcomes occur-
ring during withdrawal periods would be attributed to 
the antidepressant. This misclassification could under-
estimate associations with drug use if non-differential 
but could exaggerate the associations, since patients 
missing antidepressants for only a few days or weeks 
may have substantial changes in mood and suicidal ide-
ation. When we changed the gap to 30 days, however, 
the results were similar. The increased rates we found 
during periods shortly after antidepressants were 
started might be a consequence of patients switching 
between treatments, making these associations difficult 
to disentangle.
Some outcomes may also have been misclassified, 
especially where episodes of attempted suicide or self 
table 5 | absolute risks of attempted suicide or self harm and suicide over one year by 
antidepressant class and antidepressant drugs
Drug class and individual 
drugs
absolute risks (95% Ci) over one year (%)
suicide*
attempted suicide or 
self harm†
antidepressant classes
SSRIs 0.05 (0.01 to 0.11) 1.38 (1.17 to 1.61)
TCAs 0.04 (0.03 to 0.09) 1.37 (1.24 to 1.54)
Other antidepressants 0.17 (0.08 to 0.36) 2.70 (2.28 to 3.20)
Combined antidepressants 0.11 (0.02 to 0.77) 2.97 (1.91 to 4.62)
antidepressant drugs
SSRIs:
 Citalopram 0.05 (0.02 to 0.09) 1.42 (1.25 to 1.61)
 Escitalopram 0.05 (0.02 to 0.19) 1.61 (1.28 to 2.04)
 Fluoxetine 0.04 (0.02 to 0.09) 1.30 (1.14 to 1.48)
 Paroxetine 0.08 (0.03 to 0.21) 1.40 (1.14 to 1.71)
 Sertraline 0.04 (0.01 to 0.14) 1.41 (1.15 to 1.74)
TCAs:
 Amitriptyline 0.02 (0.00 to 0.13) 1.02 (0.80 to 1.31)
 Dosulepin 0.05 (0.01 to 0.20) 1.51 (1.19 to 1.92)
 Lofepramine 0.05 (0.01 to 0.37) 1.54 (1.12 to 2.10)
 Trazodone 0.10 (0.01 to 0.79) 2.64 (1.69 to 4.13)
Others:
 Mirtazapine 0.19 (0.07 to 0.47) 2.55 (2.03 to 3.21)
 Venlafaxine 0.14 (0.05 to 0.37) 2.96 (2.40 to 3.64)
 All other antidepressants 0.12 (0.03 to 0.53) 1.63 (1.11 to 2.41)
 Combined antidepressants 0.11 (0.02 to 0.77) 2.97 (1.91 to 4.62)
*Adjusted for confounders listed in table 2.
†Adjusted for confounders listed in table 3.
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harm are not reported. This could lead to underestima-
tion of absolute risks but is unlikely to vary according to 
the antidepressant prescribed so this would not explain 
the associations we have found. We included informa-
tion from linked death certificates to identify additional 
cases of suicide, including those recorded as open ver-
dicts, which will have reduced misclassification for this 
outcome; however, we might still have underestimated 
suicide rates since some suicides may have been 
recorded as unintentional incidents.27
The numbers of events in the suicide analyses were 
small, particularly when split into different antidepres-
sant exposure categories. So while there was sufficient 
power to detect large differences, such as between other 
antidepressants and selective serotonin reuptake inhib-
itors (adjusted hazard ratio 2.6, 95% confidence interval 
1.7 to 4.0), the power would have been low for smaller 
differences. Therefore we cannot rule out relatively 
small differences between, for example, selective sero-
tonin reuptake inhibitors and tricyclic antidepressants. 
Furthermore the small number of suicide events means 
that the multivariable models may be overfitted, so for 
individual drugs in particular the adjusted hazard 
ratios and absolute event rates derived from them 
should be interpreted with extreme caution.
A further limitation is that the underlying biology of 
suicide and attempted suicide is poorly understood so 
there is no established pharmacological rationale for 
the relations we have identified; rather, these are statis-
tical associations worthy of further investigation to 
understand any underlying biological mechanisms.
Comparison with other studies
The suicide rates in our study cohort (43 per 100 000 in 
men and 9 per 100 000 in women) are higher than those 
in the general population in England28 (three year aver-
age rates of 12.4 per 100 000 in men and 3.7 per 100 000 
in women for 2010–12). Larger differences than this 
might be expected since our rates are in patients with a 
diagnosis of depression rather than in the general pop-
ulation. Studies showing greater differences, however, 
have tended to be in secondary care settings, where 
patients have more severe depression.
These results are consistent with those of our previ-
ous cohort study in older people with depression,19 
which found that trazodone, mirtazapine, and venla-
faxine were associated with the highest rates of 
attempted suicide or self harm in people aged 65 or 
more. The number of recorded suicides in that study 
was too small (43 cases) to carry out an analysis by indi-
vidual drug, but the analysis by drug class found that 
the suicide rate was highest for the group of other anti-
depressants.
Some other observational studies of antidepressants 
and risk of suicide or attempted suicide have also found 
increased risks among patients prescribed venlafaxine, 
although fewer studies have reported increased risks for 
mirtazapine or trazodone. A cohort study9 in patients 
aged 18 to 89 using the general practice research data-
base found that venlafaxine use was associated with a 
higher risk of suicide and attempted suicide than was 
citalopram, fluoxetine, and dothiepin. The authors con-
cluded that this could reflect residual confounding 
since they found that venlafaxine users had a higher 
burden of risk factors for suicide, as was also the case in 
a previous study using the general practice research 
database.29 A study of US veterans30 with diagnosed 
depression comparing seven antidepressant medica-
tions found that crude suicide rates were highest among 
those prescribed mirtazapine, and venlafaxine had the 
second highest crude rate. In adjusted analyses, how-
ever, the suicide rates were not significantly higher for 
these drugs than for citalopram. A cohort study com-
prising all patients in Finland admitted to hospital 
because of a suicide attempt between 1997 and 2003, 
excluding patients with a diagnosis of psychosis, found 
that venlafaxine was associated with a significantly 
increased risk of suicide during follow-up and fluoxe-
tine with a significantly reduced risk when compared 
with no antidepressant treatment, even after adjusting 
for confounders.31 Mirtazapine was associated with an 
increased risk of suicide in the crude analysis, but not 
after adjustment. In the adjusted analysis all individual 
antidepressant drugs were associated with an increased 
risk of further suicide attempts compared with no anti-
depressant use, and although the adjusted relative risk 
was highest for venlafaxine it was only slightly larger 
than the relative risks for the other antidepressants 
studied. A cohort study10 based on incident users of 
antidepressants also found a significantly increased 
risk of suicide acts (suicide attempts and completed sui-
cides) for venlafaxine users compared with selective 
serotonin reuptake inhibitor users, although the associ-
ation was attenuated in a secondary analysis restricted 
to treatment naїve patients.
Although randomised controlled trials of antidepres-
sants are not influenced by residual confounding, they 
tend to be small, of short duration, and often exclude 
people who are actively suicidal or have comorbidi-
ties.32 Several meta-analyses of randomised controlled 
trials have been conducted,7 33–36 although few have 
looked at individual antidepressant drugs. The 
meta-analysis of 372 randomised controlled trials con-
ducted by Stone et al7 included an analysis of suicidal-
ity risk (suicide, attempted suicide, preparatory acts, 
or ideation) for 18 individual drugs compared with pla-
cebo. This meta-analysis included a total of 530 out-
come events, of which only eight were completed 
suicides and 134 were attempted suicides. The num-
bers of events for individual drugs were small and sta-
tistical tests found no significant differences among 
drugs and drug classes, with the exception of some 
indication of differences among selective serotonin 
reuptake inhibitors, where odds ratios for suicidality 
ranged from 0.51 (95% confidence interval 0.29 to 0.91) 
for sertraline to 2.44 (0.90 to 6.63) for escitalopram 
compared with placebo.
Clinical implications and future research
The results of this study and others on self harm, 
 suicide, and all cause mortality increasingly suggest 
that adults prescribed drugs such as mirtazapine and 
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 venlafaxine and possibly trazodone seem to be at 
higher risk of self harm and suicide. These associations 
might be due to these patients having different charac-
teristics or more severe depression than patients pre-
scribed other antidepressants rather than a direct 
causal effect of the drugs, but irrespective of the reason 
for the increased risks these patients need particularly 
close monitoring during treatment and shortly after 
stopping. The benefits and risks of different antide-
pressant treatments will vary between patients,37 and 
these should be considered carefully when antidepres-
sants are prescribed.
At present NICE guidelines for depression25 recom-
mend the use of a selective serotonin reuptake inhibitor 
first but if there is a lack of response to use another 
selective serotonin reuptake inhibitor or a better toler-
ated newer generation antidepressant, and subse-
quently an antidepressant from a different drug class, 
such as venlafaxine or a tricyclic antidepressant. The 
British Association of Psychopharmacology guide-
lines38 recommend the use of venlafaxine, escitalo-
pram, or older tricyclic antidepressants at a higher dose 
in patients with severe depression. If our findings are 
confirmed this advice may require further consider-
ation. Our results, showing an association of an 
increased risk of attempted suicide or self harm with 
combinations of antidepressants compared with selec-
tive serotonin reuptake inhibitors is, in addition to 
adverse physical outcomes, another reason for careful 
monitoring of patients taking combinations of antide-
pressants by specialists in the management of depres-
sion.25 The results also confirm that the risk of self harm 
and suicide is increased in the first 28 days of stopping 
antidepressants, so guidelines might place greater 
emphasis on the need for monitoring anyone after a 
planned withdrawal of antidepressants or an indication 
of any unplanned or sudden withdrawal. Further 
research might examine if such risk is universal or only 
applies to patients with symptoms of depression and 
other risk factors for suicide and self harm.
Conclusions
This study has found that rates of suicide and self 
harm were similar during periods of treatment with 
selective serotonin reuptake inhibitors and tricyclic 
antidepressants, but were higher for the group of 
other antidepressant drugs, with mirtazapine, venla-
faxine, and trazodone being associated with the high-
est risks. The number of suicide events was small so 
the results for suicide should be interpreted with cau-
tion. Rates tended to be highest in the first 28 days 
after starting treatment and remained increased in the 
first 28 days after stopping treatment. These findings 
are of associations rather than causal effects and are 
particularly susceptible to confounding by indica-
tion, channelling bias, and residual confounding; fur-
ther research is needed to confirm them. The results of 
this study indicate that patients taking antidepres-
sant drugs should be carefully monitored, especially 
during early treatment with antidepressants and 
when stopping treatment.
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